Browsing by Author "Mesquita-Rodrigues, A"
Now showing 1 - 10 of 12
Results Per Page
Sort Options
- Cirurgia Colorrectal Laparoscópica: A experiência de uma unidade de coloproctologiaPublication . Ribas, S; Leão, P; Pereira, R; Rosa, N; Martins, S; Lamelas, J; Mesquita-Rodrigues, A
- Clinicopathological correlation and prognostic significance of VEGF-A, VEGF-C, VEGFR-2 and VEGFR-3 expression in colorectal cancer.Publication . Martins, SF; Garcia, EA; Luz, MA; Pardal, F; Mesquita-Rodrigues, A; Filho, ALBACKGROUND: Colorectal cancer (CRC) is the third most common type of cancer and the fourth most frequent cause of cancer death. Literature indicates that vascular endothelial growth factor is a predominant angiogenic factor and that angiogenesis plays an important role in the progression of CRC. PATIENTS AND METHODS: The present series consisted of tissue samples obtained from 672 patients who had undergone large bowel resection between 2005 and 2010 at the Braga Hospital, Portugal. Archival paraffin-embedded CRC tissue and normal adjacent samples were used to build up tissue microarray blocks and VEGF-A, VEGF-C, VEGFR-2 and VEGFR-3 expression was immunohistochemically assessed. RESULTS: We observed an overexpression of VEGF-C in CRC when tumour cells and normal-adjacent tissue were compared (p=0.004). In tumour samples, VEGF-C-positive cases were associated with VEGFR-3 expression (p=0.047). When assessing the correlation between VEGF-A, VEGF-C, VEGFR-2 and VEGFR-3 expressions and the clinicopathological data, it was revealed that VEGF-A positive cases were associated with male gender (p=0.016) and well-differentiated tumours (p=0.001); VEGF-C with colon cancers (p=0.037), exophytic (p=0.048), moderately-differentiated (p=0.007) and T3/T4 (p=0.010) tumours; VEGFR-2 with invasive adenocarcinoma (p=0.007) and VEGFR-3 with the presence of hepatic metastasis (p=0.032). Overall survival curves for CRC were statistically significant for rectal cancer, VEGF-C expression and stage III (p=0.019) and VEGFR-3 expression and stage IV (p=0.047). CONCLUSION: Quantification of VEGF-A, VEGF-C, VEGFR-2 and VEGFR-3 expression seems to provide valuable prognostic information in CRC and the correlation with clinicopathological data revealed an association with characteristics that contribute to progression, invasion and metastasis leading to poorer survival rates and prognosis.
- Increased expression of monocarboxylate transporters 1, 2, and 4 in colorectal carcinomasPublication . Pinheiro, C; Longatto-Filho, A; Scapulatempo, C; Mesquita-Rodrigues, A; Alves, VA; Schmitt, F; Baltazar, FTumour cells are known to be highly glycolytic, thus producing high amounts of lactic acid. Monocarboxylate transporters (MCTs), by promoting the efflux of the accumulating acids, constitute one of the most important mechanisms in the maintenance of tumour intracellular pH. Since data concerning MCT expression in colorectal carcinomas (CRC) are scarce and controversial, the present study aimed to assess the expressions of MCT1, 2, and 4 in a well characterized series of CRC and assess their role in CRC carcinogenesis. CRC samples (126 cases) were analyzed for MCT1, MCT2, and MCT4 immunoexpression and findings correlated with clinico-pathological parameters. Expression of all MCT isoforms in tumour cells was significantly increased when compared to adjacent normal epithelium. Remarkably, there was a significant gain of membrane expression for MCT1 and MCT4 and loss of plasma membrane expression for MCT2 in tumour cells. Plasma membrane expression of MCT1 was directly related to the presence of vascular invasion. This is the larger study on MCT expression in CRC and evaluates for the first time its clinico-pathological significance. The increased expression of these transporters suggests an important role in CRC, which might justify their use, especially MCT1 and MCT4, as targets in CRC drug therapy.
- Ki-67 Expression in CRC Lymph Node Metastasis Does Not Predict SurvivalPublication . Martins, SF; Amorim, R; Mota, SC; Costa, L; Pardal, F; Mesquita-Rodrigues, A; Longatto-Filho, AColorectal cancer is one of the most common malignancies and a leading cause of cancer death worldwide. Molecular markers may improve clinicopathologic staging and provide a basis to guide novel therapeutic strategies which target specific tumour-associated molecules according to individual tumour biology; however, so far, no ideal molecular marker has been found to predict disease progression. We tested Ki-67 proliferation marker in primary and lymph node metastasis of CRC. We observed a statistical significant difference between the positive rates of neoplastic cells positively stained by Ki-67 in both sites, with remarkable increased number of Ki-67 positive cells in primary tumor cells compared to cancer cells that invaded lymph nodes. We can speculate that the metastatic CRC in lymph node can be more resistant to the drugs that target cellular division.
- Ki-67 Expression in CRC Lymph Node Metastasis Does Not Predict SurvivalPublication . Martins, SF; Amorim, R; Coelho-Mota, S; Costa, L; Pardal, F; Mesquita-Rodrigues, A; Longatto-Filho, AColorectal cancer is one of the most common malignancies and a leading cause of cancer death worldwide. Molecular markers may improve clinicopathologic staging and provide a basis to guide novel therapeutic strategies which target specific tumour-associated molecules according to individual tumour biology; however, so far, no ideal molecular marker has been found to predict disease progression. We tested Ki-67 proliferation marker in primary and lymph node metastasis of CRC. We observed a statistical significant difference between the positive rates of neoplastic cells positively stained by Ki-67 in both sites, with remarkable increased number of Ki-67 positive cells in primary tumor cells compared to cancer cells that invaded lymph nodes. We can speculate that the metastatic CRC in lymph node can be more resistant to the drugs that target cellular division.
- Lipossarcoma RetroperitonealPublication . Leão, P; Martins, S; Vilaça, S; Lamelas, J; Falcão, J; Mesquita-Rodrigues, A
- Operação de Hartmann: casuística do Departamento de CirurgiaPublication . Martins, S; Carneiro, T; Toscano, A; Soares, V; Kock, P; Mesquita-Rodrigues, Aoperação de Hartmann tem como vantagem a segurança do procedimento cirúrgico, e como principal desvantagem a necessidade de uma 2ª. intervenção cirúrgica para conclusão do tratamento. Os autores realizaram um estudo retrospectivo dos doentes submetidos a operação de Hartmann num período de 7 anos (1997-2003). (Introdução) A operação de Hartmann foi inicialmente descrita em 1921 para o tratamento de doentes com carcinoma do recto. Hoje em dia é principalmente utilizada sempre que está contra-indicada uma reconstrução num só tempo. Consiste na ressecção do segmento envolvido pela patologia, com encerramento do topo distal e construção de uma colostomia proximal terminal. Apresenta como principais vantagens a segurança do procedimento, isto é o facto de permitir remover a fonte do problema ao mesmo tempo que elimina o risco de uma anastomose sob condições desfavoráveis. A principal desvantagem resulta de necessitar de um 2º. tempo cirúrgico 'major', geralmente 6 ou mais semanas depois da 1ª. intervenção, que poderá ser dificultado pelo facto de o coto distal ser difícil de identificar e estar retraído, e ainda de ser preciso realizar a desmontagem da colostomia. No entanto alguns doentes ficam privados da 2ª. cirurgia, e a operação de Hartmann dá origem a um estoma definitivo. (Conclusões) As principais indicações para a operação de Hartmann, no Departamento de Cirurgia do Hospital de S. Marcos, foram o adenocarcinoma do cólon e a diverticulite complicada. Esta cirurgia foi realizada principalmente em doentes idosos. No entanto é relativamente segura, tendo-se verificado uma baixa morbilidade, e a mortalidade apresentada resultou da história natural da doença e não da intervenção cirúrgica. Só cerca de 50% dos doentes foram submetidos a reconstituição do trânsito, sendo este um procedimento cirúrgico seguro.
- Role of endoglin and VEGF family expression in colorectal cancer prognosis and anti-angiogenic therapiesPublication . Martins, SF; Reis, RM; Mesquita-Rodrigues, A; Baltazar, F; Filho, ALColorectal cancer (CRC) is one of the cancer models and most of the carcinogenic steps are presently well understood. Therefore, successful preventive measures are currently used in medical practice. However, CRC is still an important public health problem as it is the third most common cancer and the fourth most frequent cause of cancer death worldwide. Nowadays, pathologic stage is a unique and well-recognized prognostic indicator, however, more accurate indicators of the biologic behavior of CRC are expected to improve the specificity of medical treatment. Angiogenesis plays an important role in the growth and progression of cancer but its role as a prognostic factor is still controversial. Probably the most important clinical implication of tumor angiogenesis is the development of anti-angiogenic therapy. The goal of this review is to critically evaluate the role of angiogenic markers, assessed by either endoglin-related microvessel density or expression of vascular endothelial growth factor family members in the CRC setting and discuss the role of these angiogenic markers in anti-angiogenic therapies.
- The influence of metabolic syndrome in the outcomes of colorectal cancer patientsPublication . Goulart, A; Varejão, A; Nogueira, F; Martins, S; Mesquita-Rodrigues, A; Sousa, N; Leão, PAIMS: Determine the influence of metabolic syndrome and its different components in the outcomes of colorectal cancer surgery at 30days. MATERIALS AND METHODS: Prospective study that included all patients submitted to elective colorectal cancer surgery between August 2015 and August 2016 at Hospital de Braga. Clinical and laboratory parameters evaluated pre-operatively were: central obesity, blood pressure, fasting glucose, triglycerides levels and HDL cholesterol levels. Any complications during the first 30-days after surgery were recorded (readmission, reintervention, anastomotic dehiscence, morbimortality). RESULTS: One hundred and thirty-four patients were included. Metabolic syndrome was diagnostic in 40.7% of patients with the ATPIII definition, 67.5% with the AHA definition and 67.0% with the IDF definition. At 30days after colorectal cancer surgery, 73.1% patients don't have any complication, 15.7% have minor complications (grade I/II of Clavien-Dindo classification), 11.1% have major complications (grade III/IV/V of Clavien-Dindo classification) and 1.5% have died from surgical complications (grade V of Clavien-Dindo classification). The statistic analysis didn't reveal any association between MS, or it's different components, and surgical outcomes. CONCLUSION: This study seems to indicate that metabolic syndrome don't have any influence in surgical outcomes of colorectal cancer surgery.
- Tumor de Krukenberg: A propósito de um caso clínicoPublication . Ribas, S; Campelos, S; Lamelas, J; Mesquita-Rodrigues, A